Lung Adenocarcinoma
Conditions
Keywords
MAB C225(CETUXIMAB)(ANTI-EGFR), OSI-774, TARCEVA (ERLOTINIB), Lung, Adenocarcinoma, Lung cancer
Brief summary
The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that initially became smaller after taking erlotinib and then started to get bigger despite continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug administration for treatment of head and neck and colon cancer. The goal of the phase I portion of this trial is to find out the highest dose of cetuximab that can be taken together with erlotinib. This study will also give an idea of how well cetuximab shrinks lung cancer when given with erlotinib. The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that initially became smaller after taking erlotinib or gefitinib and then started to get bigger despite continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug administration for treatment of head and neck and colon cancer. The goal of this phase is to determine if cetuximab given with erlotinib causes lung cancers to shrink in size.
Interventions
DRUGerlotinib with cetuximab
The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
Sponsors
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologic evidence of lung adenocarcinoma confirmed at MSKCC * Measurable (RECIST) indicator lesions not previously irradiated * Radiographic progression by RECIST during treatment with erlotinib * Received treatment with erlotinib throughout the one month prior to enrollment * Received treatment with erlotinib for \>3 months * At least one of the following: * Previously received treatment with erlotinib, gefitinib, or an investigational EGFR TK inhibitor (patients may have received other treatments subsequently including radiation or chemotherapy) and had a radiographic partial or complete response to treatment as defined by RECIST criteria * A documented mutation in EGFR exons 19 or 21. * Karnofsky performance status ≥ or = to 70% * Total bilirubin: within normal institutional limits. AST/(SGOT)/ALT(SGPT)\< or = to 2.5 X institutional upper limit of normal (ULN) * Signed informed consent * Effective contraception \* * Age \> 18 years old \*Sexually active women of childbearing potential must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control. All WOCBP MUST have a negative pregnancy test within two weeks prior to first receiving investigational product. If the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study. In addition, all WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study participation. The Investigator must immediately notify BMS in the event of a confirmed pregnancy in a patient participating in the study.
Exclusion criteria
* CNS lesions which are symptomatic and/or requiring escalating doses of corticosteroids. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Prior cetuximab or panitumumab. Prior severe infusion reaction to a monoclonal antibody. * Current grade 2 or greater skin toxicity on erlotinib therapy * Radiotherapy ≤ or = to 14 days prior to enrollment * Any investigational agent or therapy ≤ or = to 30 days before enrollment * Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved proteins/antibodies (except erlotinib) ≤ or = to 30 days before enrollment * Women who are pregnant or lactating. * Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection * Major surgery within 28 days or minor surgery within 14 days of study enrollment * Men or women of child-bearing potential (women who are post-menopausal \< 52 weeks, not surgically sterilized, or not abstinent) not consenting to use adequate contraception (per institutional standard of care) during the course of the study and after the last investigational product(s) administration (24 weeks for women, 4 weeks for men)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks | At conclusion of study, up to 24 weeks | To determine the maximum tolerated dose (MTD) of cetuximab given every 2 weeks in patients with lung adenocarcinoma receiving erlotinib that have developed acquired resistance to erlotinib (phase I portion) |
Countries
United States
Participant flow
Recruitment details
Protocol Open to Accrual: 7/15/2008 Protocol Closed to Accrual: 5/25/2010 Primary Completion Date: 5/24/2011 Recruitment Location is the Medical Clinic
Participants by arm
| Arm | Count |
|---|---|
| Cetuximab 250 mg/m2 Cetuximab 250 mg/m2 IV every two weeks | 3 |
| Cetuximab 375 mg/m2 Cetuximab 375 mg/m2 IV every two weeks | 5 |
| Cetuximab 500 mg/m2 Cetuximab 500 mg/m2 IV every two weeks | 13 |
| Total | 21 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 | 0 |
Baseline characteristics
| Characteristic | Cetuximab 250 mg/m2 | Cetuximab 375 mg/m2 | Cetuximab 500 mg/m2 | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 3 Participants | 4 Participants | 9 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 2 Participants | 9 Participants | 12 Participants |
| Region of Enrollment United States | 3 participants | 5 participants | 13 participants | 21 participants |
| Sex: Female, Male Female | 1 Participants | 4 Participants | 9 Participants | 14 Participants |
| Sex: Female, Male Male | 2 Participants | 1 Participants | 4 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 3 / 3 | 3 / 5 | 12 / 13 |
| serious Total, serious adverse events | 3 / 3 | 2 / 5 | 5 / 13 |
Outcome results
Primary
The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks
To determine the maximum tolerated dose (MTD) of cetuximab given every 2 weeks in patients with lung adenocarcinoma receiving erlotinib that have developed acquired resistance to erlotinib (phase I portion)
Time frame: At conclusion of study, up to 24 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cetuximab 250 mg/m2 | The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks | 500 mg/m2 of CETUXIMAB |
| Cetuximab 375 mg/m2 | The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks | 500 mg/m2 of CETUXIMAB |
| Cetuximab 500 mg/m2 | The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks | 500 mg/m2 of CETUXIMAB |